𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adjuvant immunotherapy with BCG in stage II malignant melanoma

✍ Scribed by M. J. Byrne; G. van Hazel; P. M. Reynolds; W. M. Lemish; C. D. J. Holman

Publisher
John Wiley and Sons
Year
1983
Tongue
English
Weight
223 KB
Volume
23
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Forty‐one patients were treated with BCG immunotherapy following block dissection of lymph nodes involved with malignant melanoma. A control group of similar patients who received no immunotherapy was drawn from a population consisting of all patients with malignant melanoma diagnosed in Western Australia in the period from January 1, 1975 to December 31, 1976. The disease‐free survival and overall survival of BCG‐treated patients were not different from that of the control group, who received no immunotherapy. The findings do not support the use of this type of immunotherapy as an adjuvant to surgery in the treatment of patients with stage II malignant melanoma.

πŸ“œ SIMILAR VOLUMES

Adjuvant treatment of malignant melanoma
Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG
✍ Dr. Constantine P. Karakousis; Lawrence J. Emrich πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 338 KB

Eighty-two patients with invasive malignant melanoma and no distant metastases were prospectively randomized following their surgical treatment to 1) observation; 2) chemotherapy with Dacarbazine (DTIC) 200 mg/M2 I.V. daily X 5 every 4 weeks and Estracyt 15 mg/kg orally daily for 1 year; and 3) immu

Granulomas in melanoma patients treated
Granulomas in melanoma patients treated with BCG immunotherapy
✍ Constantine Hatzitheofilou; Dean F. Obenchain; David D. Porter; Donald L. Morton πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 672 KB

Autopsy slides from 22 melanoma patients who received bacille Calmette-Guerin BC'G immunotherapy and who had a postmortem examination at the U C L A Center for the Health Sciences were examined for the presence o f granulomas. Granulomas were found i n six patients (29%) who received BCX but not in